CD4 and non-small cell lung carcinoma: In non-small cell lung carcinoma (NSCLC), female-gender patients produce a stronger anti-tumor immune response than male patients, and they have a higher number of activated dendritic cells, CD4+, CD8+, and effector T cells, memory CD4+ T cells, and B cells [68].